Chelsea Counsel Company’s Avanos Medical AVNS Stock Holding History

Chelsea Counsel Company’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$135	–	154
2022 Q4	$135	Buy	+5	New	+$122	﹤0.01%	162

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Chelsea Counsel Company's AVNS Position: Q1 2023 in Review

Chelsea Counsel Company sold out of Avanos Medical (AVNS) in Q1 2023, closing a stake of 5 shares — an estimated $135 sold.

Chelsea Counsel Company first reported a position in AVNS in Q4 2022 and held it in 1 quarter. The position peaked at $135 in Q4 2022. 287 funds tracked by Wall St. Rank hold AVNS as of Q1 2023.

Chelsea Counsel Company reported no remaining Avanos Medical position as of Q1 2023 after selling out during the quarter.
Chelsea Counsel Company sold 5 Avanos Medical shares in Q1 2023, an estimated $135.
Chelsea Counsel Company first reported a position in Avanos Medical in Q4 2022 and held it in 1 quarter.
Chelsea Counsel Company's Avanos Medical position peaked at $135 in Q4 2022.
287 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2023.

Based on Chelsea Counsel Company's 13F filing for Q1 2023, filed 19 May 2023.